projects:workgroups:transfusion

OHDSI Transfusion Working Group

MISSION

Extend OMOP CDM and Vocabulary and OHDSI analytic platform to support transfusion research

Transfusions are special treatments which are currently in active research by the FDA BEST and the REDS-IV program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap.

Use Cases

Effect of number of units on outcomes
Effect of single donor vs pooled on outcomes
Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes
Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others
Fatality rates of outcomes
Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood
Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction
Incidence rates of outcomes by indication and associated procedures and other possible risk factors
Incidence rates of outcomes by donor characteristics

Modelling Issues

Detailed facts about transfused units, such as
Manipulation: cultured enrichment, demineralization, genetical modification,
Concentration, dosage, portioning and unit of issue,
Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection,
monitoring: preparation, processing, mobilization, modification, quarantine,
Additive, excipient and nutrient content
Dose
Units
Route
Start/End Time
Multiple touch points of interest (prescribe/dispense/admin)
Lab results specific to the unit for unit-specific data (product CD34+ vs patient CD34+)

* Participants

* Forum discussions

* Data Repository